19 jun: Investeringsselskabet Artha Optimum A/S – ledende medarbejderes t..
19 jun: Ordinær generalforsamling - Harboes Bryggeri A/S
19-06-2019 17:36:00

Major Shareholder Announcement

Company Announcement

  • Major shareholder announcement for Genmab A/S

Copenhagen, Denmark; June 19, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of June 18, 2019, BlackRock, Inc. has increased their total ownership (indirectly owned shares and financial instruments) in Genmab A/S to 3,086,679 shares, which amounts to 5.00% of the share capital and voting rights in Genmab A/S.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 27

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
11:40 - 
Aktier/middag: Ambu sendes i dybet oven på regnskab i r..
09:13 - 
Aktier/åbning: Ambu hamres ned efter regnskab mens GN b..
07:55 - 
Aktier/tendens: GN og Ambu til eksamen i negativt marke..
Relateret debat
15:51 - 
De blev for nyligt noteret i USA.   Ser ud til at ..
15:09 - 
Dagens joke/positive overraskelse Da jeg følger ..
14:18 - 
Er der nogen, der ved hvor stort markedet er i Japan?
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 aug
GEN
Lige i dette tilfælde er der måake ikke det vilde nye - men det er stadig data på disse konference d..
15
19 aug
GEN
https://ir.genmab.com/news-releases/news-release-details/daratumumab-abstracts-selected-presentation..
8
19 aug
GEN
Det altid fint at tage gevinst, og tillykke med den. Og fint du melde rent flag/ da du har været den..
7
19 aug
GEN
Ha-ha-ha...   I fredags kunne du - og mange andre, måtte man forstå - se store stigninger i den komm..
5
19 aug
GEN
Jeg har solgt alle mine Genmabs i den frie, tror stadig på gen men er bange for at vi skal ned gener..
5
16 aug
GEN
Hopla og hopla - men der er gode udsigter:   https://finans.dk/investor/ECE11555850/genmabtopchef-vi..
4
19 aug
GEN
Han melder da rent flag, og må man ikke ændre menig ? Der kan være alle mulige grunde til hans besl..
3
10:36
GEN
En analytiker som var gæst i Millionærklubben i dag, mente at Genmab ligger i stærk stigende trend. ..
2
20 aug
GEN
Ja der er mange gode nyheder fra Genmab for tiden :-) så man kan godt blive lidt nyheds resistent. M..
2
20 aug
GEN
Det er jo blot kendt viden, der bliver fremlagt paa en konference. Hvis man foelger lidt med, ved ma..
2

Parken minimerer underskud efter frasalg af Fitness.dk

22-08-2019 14:50:04
Parken Sport & Entertainment er på vej til en vending på bundlinjen efter frasalget af den tabsgivende Fitness.dk-kæde sidste år.På bundlinjen lander selskabet et underskud på 12,8 mio. kr. for andet kvartal mod det massive underskud på 213,2 mio. kr. i samme kvartal sidste år.- Resultat af ophørende aktiviteter udgjorde 0,0 mio.kr. mod -219,7 mio.kr. i samme periode sidste år og kan henføres til ..

Jeudan opjusterer efter fremgang i kurs- og værdiregulering

22-08-2019 14:00:42
Efter en markant fremgang i kurs- og værdireguleringen i andet kvartal kan ejendomsselskabet Jeudan notere betydelig fremgang i nettooverskuddet for årets andet kvartal og for første halvår, der blev præsenteret torsdag middag.Det vækker tilfredshed hos administrerende direktør Per W. Hallgren.- Vi aflægger i dag et regnskab for de første seks måneder med et tilfredsstillende resultat. Det bekræft..

Aktier/middag: Ambu sendes i dybet oven på regnskab i rødt marked

22-08-2019 11:40:08
Ambu bliver torsdag ved middagstid straffet på børsen i København, efter at selskabet natten til torsdag nedjusterede sine forventninger til regnskabsåret 2018/19. Det takserer investorerne til et kursfald på 13,3 pct. til 96,1 kr. i et svagt negativt aktiemarked, hvor det danske C25-indeks falder 0,1 pct. til 1141,08.Ambu sænkede sine forventninger, da selskabet i fremtiden selv vil stå for salge..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/middag: Ambu sendes i dybet oven på regnskab i rødt marked
2
Juan José Gonzales: Det er en af de vigtigste investeringer i år
3
Ambu dæmper forventninger til de kommende fem kvartaler
4
Aktier/tendens: GN og Ambu til eksamen i negativt marked
5
Ambu/Sydbank: Nedjustering bidrager til usikkerhed omkring fremtiden

Relaterede aktiekurser

Genmab A/S 1.378,50 0,2% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. august 2019 19:59:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190819.1 - EUROWEB1 - 2019-08-22 19:59:22 - 2019-08-22 19:59:22 - 1 - Website: OKAY